Statements, Letters, and Regulatory Comments

Statements, Letters, and Regulatory Comments

By educating elected officials and other government decision-makers on the needs of the cystic fibrosis community, the Cystic Fibrosis Foundation works to shape public policy to help our efforts to cure CF and provide all people with CF the opportunity to live full, healthy lives. Below find a listing of our state and federal statements, letters, and regulatory comments.

Statements, letters, and regulatory comments issued before July 2023 can be found in our archive.
Drug Pricing and Access | Prior Authorization CF Foundation Supports New Jersey’s Efforts to Reform Prior Authorization

The Cystic Fibrosis Foundation expressed support to the New Jersey General Assembly for A1255, Ensuring Transparency in Prior Authorization, which makes several important reforms to the prior authorization process.
Drug Pricing and Access CF Foundation Asks New Jersey Medicaid to Update Trikafta Eligibility Criteria

CF Foundation sends a letter to Amerigroup and New Jersey Medicaid asking the groups to update their Trikafta® eligibility criteria to reflect the recent label expansion to people with CF between ages two and five.